Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Sepsis is sometimes called septicemia or blood poisoning. Sepsis is more common in people with chronic medical conditions, such as diabetes, lung disease, cancer, and kidney disease, people with weakened immune systems, babies under 1 year of age, and elderly people especially if they have other health problems.
Each year, at least 1.7 million adults in the US develop sepsis and nearly 270,000 die as a result. The number of sepsis cases per year has been on the rise in the United States. In the Sepsis treatment pipeline, there are 45+ drugs in different phases of development.
DelveInsight adds a new edition to its newsletter series that pivots around the sepsis space. The newsletter offers a complete picture of the sepsis market landscape, ongoing clinical trials, and pipeline therapies expected to transform the sepsis market in the coming decade.
Get a sneak peek of the sepsis pipeline therapies, clinical trials, deals & tie-ups, and upcoming world-class conferences, as well as track all the recent updates in the sepsis market.
Interested in knowing more about what upcoming years hold for the sepsis market and how pharma companies work to push drug development? Download our Newsletter by simply filling up the form on the right.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- R&D in the field
- Top conferences
- News Flash
- Recent Research Activities
- Support from International organizations
- Market insights
- Market Dynamics
- Collaborations and deals in the domain